Morgan Stanley Abeona Therapeutics Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 177,346 shares of ABEO stock, worth $1.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

177,346

Previous 595,998 70.24%

Holding current value

$1.06 Million

Previous $2.53 Million 55.68%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.12 - $6.32 $1.72 Million - $2.65 Million	-418,652 Reduced 70.24%	177,346 $1.12 Million
Q2 2024 Oct 17, 2024	BUY	$3.17 - $8.05 $1.79 Million - $4.55 Million	564,963 Added 1820.41%	595,998 $2.53 Million
Q2 2024 Aug 14, 2024	BUY	$3.17 - $8.05 $1.79 Million - $4.55 Million	564,963 Added 1820.41%	595,998 $2.53 Million
Q1 2024 Oct 17, 2024	SELL	$4.07 - $8.68 $2.3 Million - $4.9 Million	-564,963 Reduced 94.79%	31,035 $225,000
Q1 2024 Aug 16, 2024	BUY	$4.07 - $8.68 $61,880 - $131,970	15,204 Added 96.04%	31,035 $225,000
Q1 2024 May 15, 2024	BUY	$4.07 - $8.68 $61,880 - $131,970	15,204 Added 96.04%	31,035 $225,000
Q4 2023 Aug 16, 2024	SELL	$3.71 - $5.14 $2.15 Million - $2.98 Million	-580,167 Reduced 97.34%	15,831 $79,000
Q4 2023 Feb 13, 2024	BUY	$3.71 - $5.14 $41,258 - $57,161	11,121 Added 236.11%	15,831 $79,000
Q1 2023 May 15, 2023	SELL	$2.25 - $3.27 $9 - $13	-4 Reduced 0.08%	4,710 $13,000
Q4 2022 Feb 14, 2023	SELL	$2.4 - $5.65 $4 - $11	-2 Reduced 0.04%	4,714 $14,000
Q3 2022 Nov 14, 2022	BUY	$2.79 - $5.56 $13,157 - $26,220	4,716 New	4,716 $14,000

Others Institutions Holding ABEO

# of Institutions

Shares Held

26.9M

Call Options Held

614K

Put Options Held

45K

View Full List

About ABEONA THERAPEUTICS INC.

Ticker ABEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,950,380
Market Cap $35.6M
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...

More about ABEO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account